



## **Novus Therapeutics to Present at the 2018 Piper Jaffray Healthcare Conference**

November 15, 2018

IRVINE, Calif.--(BUSINESS WIRE)--Nov. 15, 2018-- Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that management will participate in the 30th Annual Piper Jaffray Health Care Conference to be held November 27-29, 2018 at the Lotte New York Palace. Gregory J. Flesher, CEO of Novus Therapeutics, is scheduled to present a company overview at 12:50 pm EST on Wednesday, November 28, 2018.

### **About Novus Therapeutics**

Novus Therapeutics, Inc. ("Novus") is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat ("ENT"). Novus has two technologies, each that has the potential to be developed for multiple ENT indications. Novus' lead product candidate (OP-02) is a surfactant-based, combination drug product being developed as a potential first-in-class treatment option for patients at risk for, or with, otitis media ("OM" or middle ear inflammation with or without infection). Globally, OM affects more than 700 million adults and children every year, with over half of cases occurring in children under five years of age. OM is one of the most common disorders seen in pediatric practice, and in the United States is a leading cause of health care visits and the most frequent reason children are prescribed antibiotics or undergo surgery. Novus also has a foam-based drug delivery technology (OP-01), which may be developed in the future to deliver drugs into the ear, nasal, and sinus cavities. For more information please visit [novustherapeutics.com](http://novustherapeutics.com).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20181115005013/en/>

Source: Novus Therapeutics, Inc.

LifeSci Advisors, LLC  
Timothy McCarthy, (212) 915-2564  
[tim@lifesciadvisors.com](mailto:tim@lifesciadvisors.com)